Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Contributed by: PR Newswire

Tags

BerGenBio-Data

More Like This

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio Reports Third Quarter 2023 Financial Results

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us